Cutaneous Leishmaniasis Clinical Trial
Official title:
Treatment of Bolivian Cutaneous Leishmaniasis With a Combination of Short Courses of Miltefosine and Antimony
Cutaneous leishmaniasis is endemic in the New World and, until recently, the standard
treatment was pentavalent antimony. The cure rate for L panamensis in Colombia is 91%-93%
and the cure rate in Bolivia is also 90%. Nevertheless, pentavalent antimonials have the
disadvantages of multiple injections and mild-moderate clinical toxicity all of which are
particularly unpleasant for a moderate clinical problem such as cutaneous leishmaniasis.
The oral agent Miltefosine has now been shown to be as effective as antimony in Colombia and
Bolivia (91 and 92% respectively). Side effects seen in patients with cutaneous disease that
can be specifically attributed to the drug are nausea and vomiting of mild grade in
approximately 25% of patients, and low-grade elevation of creatinine also in approximately
25% of patients. A further disadvantage of miltefosine is that regimens shorter than 4 weeks
have not been evaluated for cutaneous disease.
Combination therapy is now being used for many infectious diseases, such as tuberculosis,
malaria, and HIV. Combination therapy offers the potential of preventing drug resistance,
because organisms resistant to one of the drugs may be susceptible to the other drug; and
also the potential to diminish drug therapy duration and thus side effects. These two
potential benefits to some extent contradict each other: preventing resistance is best done
if full courses of both drugs is used; diminishing therapy duration means using less than
the full course of each drug. The optimum combination regimen is one in which sufficient
amounts of both drugs are used to have high efficacy, yet the amounts are as low as possible
to spare patients unnecessarily long courses of drug.
In the present protocol, the combination of a half-course of miltefosine and a half-course
of antimony will be evaluated for efficacy and tolerance. The combination of miltefosine and
antimony is chosen because these are now the two standard agents in Bolivia, and in vitro
the combination was additive to mildly synergistic against a standard leishmania strain.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01988909 -
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
| Enrolling by invitation |
NCT00737386 -
Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank
|
N/A | |
| Enrolling by invitation |
NCT00840359 -
Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT00233545 -
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
|
Phase 2 | |
| Completed |
NCT01462500 -
Pharmacokinetics of Miltefosine in Children and Adults
|
Phase 4 | |
| Completed |
NCT01011309 -
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT01301924 -
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT02281669 -
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
|
N/A | |
| Completed |
NCT01464242 -
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
| Completed |
NCT01790659 -
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
|
Phase 3 | |
| Completed |
NCT01050907 -
Miltefosine to Treat Mucocutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT04340128 -
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
|
Phase 3 | |
| Terminated |
NCT00317629 -
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
|
Phase 3 | |
| Completed |
NCT00351520 -
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
|
Phase 3 | |
| Completed |
NCT01381055 -
Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
| Completed |
NCT01050777 -
Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
|
Phase 0 | |
| Completed |
NCT01380314 -
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT00703924 -
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
|
Phase 2 | |
| Completed |
NCT00344084 -
Surveillance for Leishmaniasis Skin Lesions in Mali
|
||
| Completed |
NCT03023111 -
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
|
Phase 3 |